Journal of Computational Medicine and Informatics
Vol. 1, No. 3, Jul - Sep 2025, pp. 10-18
ISSN: 3107-3735 (O), DOI: https://doi.org/10.17051/JCMI/01.03.02

Computational Modeling of Drug Response Dynamics Using Patient-Specific Multi-Scale Data

Abolfazl Mehbodniya

Professor, Department of Electronics and Communication Engineering, Kuwait College of Science and Technology (KCST), Doha Area, 7th Ring Road, Kuwait, Email: a.niya@kcst.edu.kw
https://orcid.org/0000-0002-0945-512X

Article Info

Article history:

Received : 10.07.2025
Revised : 09.08.2025
Accepted : 07.09.2025

Keywords:

Drug response modeling,
multi-scale data integration,
Precision medicine,
Machine learning in healthcare,
Pharmacodynamics modeling,
Patient-specific prediction,
Regression modeling (RMSE, MAE, R^2),
Systems biology.

ABSTRACT

Inter-patient variability is one of the biggest challenges of drug response prediction because of multiple scales of complexity biological processes. The combination of patient specific multi-scale multi-genomic, molecular, and clinical data presents a bright opportunity to enhance drug response predictability and achieve precision medicine. The purpose of the study is to create a computational model of the prediction of the dynamics of continuous drug responses (e.g., IC50 values, tumor progression, or biomarker levels, etc.) with the use of patient-specific multi-scale data. A heterogeneous multi-scale computational architecture was created that fuses machine learning and mechanistic modeling in order to incorporate a variety of heterogeneous multi-scale data. The methods used to create informative representations were data preprocessing and feature engineering and dimensionality reduction. Cross-validation strategies were implemented to train and validate the model and the predictive performance of the model estimated based on regression measures such as Root Mean Square Error (RMSE), Mean Absolute Error (MAE) and the coefficient of determination (R 2). The proposed model had better predictive power than baseline methods and was found to have lower values of RMSE and MAE and a higher value of R 2 in a variety of datasets. Also, the incorporation of multi-scale characteristics was crucial in promoting robustness and generalizability of the model when modeling patient-specific drug response dynamics. The resulting computer model is a good predictor of continuous drug response when multi-scale patient data are used, demonstrating that the model could be useful in the future in support of personalized treatment and in the development of computational medicine.

1. INTRODUCTION

Drug variation in different patients is one of the outstanding challenges in clinical practice that can lead to inconsistent therapeutic effects and side effects. This fluctuation is motivated by intricate interactions between various biological levels that include genetic variation, cellular dynamics and physiological states. Therefore, the dynamics of drug responses are crucial to comprehend and forecast to promote precision medicine and personalized treatment plans.

Recent developments underline the significance of incorporating patient-specific multi-scale data such as genomic, molecular and clinical data into defining response to drugs behavioral patterns. Mathematical and computational modeling techniques have been extensively used to investigate tumor progression, angiogenesis and drug delivery processes. An example is that angiogenesis-mediated chemotherapy resistance and optimal treatment timing have been modeled mathematically [1] and biologically based models that use imaging information have enhanced the dynamics of tumor vasculature [2]. Also, computational models have been established to spatiotemporally model the delivery of drugs within the complicated tumor settings [3]. The experimental research also shows that tumor vasculature modulation can greatly impact the drug penetration and therapeutic efficacy [4], [6].

Simultaneously, chemical biology, as well as drug discovery, has been directed towards discovering molecular targets and elucidating drug-protein interactions. The methods of small-molecule identification, interactome screening, and phenotypic screening have helped to reveal the drug action mechanisms [7], [10]. Moreover, the design approach of sequence-specific drugs, like

the antisense oligonucleotides, underscores the role played by molecular-level specificity in therapeutic interventions [11]. The current developments notwithstanding, most of the current methods are mainly based on either biological processes or the molecular interactions without a comprehensive integration of multi-scale data into predictive computational processes.

Nonetheless, there are still a number of constraints. Most of the existing models are based on single-scale or fixed-point representations, which restricts the capability of a dynamic drug response over time. Issues with data heterogeneity, absence of integrated approaches, and inferior predictability further limit their clinical usage. As such, it is required to have strong computational frameworks that would be capable of including heterogeneous multi-scale data and model the continuous dynamics of drug responses.

In an effort to deal with the mentioned issues, the following study outlines a computational modeling framework of predicting continuous drug response based on patient-specific multi-scale data. The solution offers a combination of various types of data and the use of dynamic modeling to improve predictive accuracy and clinical applicability.

This paper introduces a new patient-oriented multi-scale computer-based model that incorporates genomics, cellular, and clinical data, which would better model the dynamics of drug responses. The suggested solution makes it possible to correctly predict the outcomes of continuous drug responses, including IC50 level, tumor metastasis, and biomarker changes by integrating dynamic modeling methods. The framework takes a hybrid modeling approach, which blends machine learning-based data approach and mechanistic understanding, and in doing so, can be used to represent both complex patterns and the underlying biological processes. Moreover, the model is strictly tested with conventional regression indicators (RMSE, MAE and R 2) and shows better predictability than a baseline methodology. Altogether, this publication enhances the development of precision medicine, as the given tool is now a powerful and scalable tool to use to develop an individual approach to treatment and make clinical decisions.

2. LITERATURE REVIEW

The initial work in pharmacology was mainly based on statistical and mechanistic, including dose-response and pharmacokinetic/pharmacodynamic (PK/PD) models, to approximate the drug response. These methods are very interpretable and yield information on the biological processes; but they are frequently not able to reflect patient-specific variability and intricate interactions at the tumor microenvironment. Mathematical modeling has been used to explore chemotherapy resistance and optimize treatment schedules especially in tumor progression based on angiogenesis [1]. Correspondingly, biologically inspired models based on imaging and vascular dynamics have enhanced the knowledge of tumor growth and application of drugs delivery mechanisms [2]. Spatiotemporal computational models have also been used to simulate drug delivery and response to treatment in a complex tumor system [3]. It is also experimentally established that tumor vasculature modulation has a great impact on drug penetration and therapeutic efficacy [4], [6].

As more and more high-dimensional biomedical data becomes accessible, machine learning methods have become popular to create complex models of the structuring of biological variables and drug responses. Regression model, ensemble learning based techniques and deep learning architectures have demonstrated enhanced predictive accuracy, especially in drug discovery and molecular analysis. Protein targets have been identified by these techniques, therapeutic interactions of drugs and proteins determined, and compounds of interest ranked by these techniques [7], [10], [12]. Also, sequence-specific drug design has been improved, including antisense oligonucleotides, which point to the increased significance of molecular-level specificity in the development of therapeutics [11]. Although they have these benefits, machine learning models are often inexplicable and do not always represent biological processes, which restricts their applicability to clinical use.

Multi-scale data combining genomic, transcriptomic, cellular, and clinical data have become an encouraging approach that can enhance drug response prediction. Multi-scale modeling has been demonstrated to offer a more detailed representation of the biological systems and has demonstrated a higher predictive power. The analyses of tumor vasculature and angiogenesis show that the combination of spatial and temporal biological data can be used to enhance the modeling results [2], [3]. Moreover, there is experimental evidence that the tumor microenvironment (vascular permeability and interstitial pressure) modification is a key factor in drug delivery as well as response [4] to [6]. Nevertheless, there are still significant barriers to successful multi-scale integration, including the heterogeneity of the data, feature selection, and the computational complexity.

Drug response is dynamic in nature and varies with time, owing to factors like tumor progression, adaptation to the treatment and resistance mechanisms. To address these dynamics, time-series and longitudinal modeling methods have

been elaborated and spatiotemporal models can shed light on the treatment response patterns [3]. Mathematical models that include angiogenesis and the timing of treatment further underscore the relevance of time dynamics in treatment effects [1]. However, most of the existing methods use static or snapshot predictions, which restricts their capability to predict continuous drug response.

Nevertheless, despite the significant advancements, there are still some important gaps in the literature. Not many studies can combine smoothly both multi-scale data as well as temporal dynamics in a single computation framework. Furthermore, little focus has been on individual patient modeling, which is critical in achieving individualized treatment approaches. Also, some of the current models have not been rigorously validated with standardized regression measures like, Root Mean Square error (RMSE), Mean Absolute error (MAE) and coefficient of determination (R^2) which are essential in assessing predictive performance in continuous drug response tasks. Thus, there is an apparent necessity of strong computational methods which combine heterogeneous multi-scale data, involve dynamic modeling and make precise and clinically relevant predictions. This paper will deal with these issues by providing a multi-scale, patient-specific computational model of continuous drug response prediction.

3. MATERIALS AND METHODS

3.1 Data collection and Preprocessing.

This paper employs patient-specific multi-scale data that combines genomic, clinical, and phenotypic data to model the dynamics of drug response. Genomic data encompasses somatic mutation data, copy number variations and expression levels of the genes obtained through high-throughput sequencing platforms. Clinical records include patient demographics (e.g., age, gender), stage of disease, and treatment history, and treatment outcomes. When feasible, imaging and phenotypic data are also included e.g. size measurement of the tumor, morphological features that would capture the progression of the disease.

Participation criteria were the presence of complete or informative enough multi-modal records and non-random samples (large number of missing data) or samples with inconsistent annotations were excluded to guarantee the quality of data. Standardization and harmonization of heterogeneous datasets were done through the use of preprocessing steps. Normalization of continuous variables was done through the use of z-score normalization or min-max scaling whereas categorical variables were coded with the help of one-hot or ordinal encoding. Statistical normalization was done on the batch effects across the datasets to eliminate systematic bias.

Both statistical imputation (mean/median imputation) and model-based imputation (k-nearest neighbors (KNN) imputation) were used to address missing data based on the type of data and pattern of missingness. Interquantile range (IQR) and z-score thresholds were also used to identify outliers and eliminate them. Table 1 provides a detailed overview of the dataset characteristics, such as sample size, dimensions of features, and data modalities.

Table 1. Summary of Patient-Specific Multi-Scale Dataset Characteristics

Data Type	Feature Category	Number of Features	Description	Source/Modality
Genomic Data	Gene Expression	5,000	Normalized RNA-seq expression levels	High-throughput sequencing
Genomic Data	Somatic Mutations	500	Binary mutation status across selected genes	Whole-exome sequencing
Genomic Data	Copy Number Variations (CNV)	300	Amplification/deletion events	Genomic profiling platforms
Clinical Data	Demographics	5	Age, gender, ethnicity, etc.	Electronic health records (EHR)
Clinical Data	Treatment History	10	Drug type, dosage, duration	Clinical records
Clinical Data	Disease Characteristics	8	Cancer stage, subtype, biomarkers	Clinical annotations
Phenotypic Data	Tumor Size	3	Baseline and follow-up measurements	Imaging (MRI/CT)
Phenotypic Data	Imaging Features	50	Radiomic features (texture, shape, intensity)	Medical imaging analysis
Drug Response Data	IC50 Values	1	Drug sensitivity measurement	Experimental assays
Drug	Biomarker Levels	5	Protein/metabolite	Laboratory assays

Response Data			response indicators	

3.2 Feature Engineering

The use of feature engineering is vital in developing a uniform and informative model of multi-scale data that has heterogeneous features. First, the raw features of various data sources were harmonized and converted to shared biological concepts (e.g., genes or pathways). Derived features (pathway activity scores, composite clinical indices) were also obtained to reflect greater amounts of biological information.

Dimensionality reduction methods were used to reduce the high level of genomic data. Principal Component Analysis (PCA) was applied to project features into lower dimensional spaces and retain variance, and autoencoders were employed to learn nonlinear representations of features. Also, feature scaling made sure that all the variables had equal weights at model training.

Selection of features was carried out to reach the most pertinent predictors of the drug response. Such techniques like correlation-based filtering, mutual information analysis or regularization were used to remove redundant, or non-informative, features (e.g., LASSO). The step does not only help to improve the model performance but also strengthens the interpretability, as it puts an emphasis on biologically important variables.

3.3 Computational Model Design

The suggested computational model, as shown in Fig. 1, unites the data preprocessing and feature engineering processes with predictive modeling into a single pipeline. To provide insights into both mechanistic and data-driven patterns, the hybrid approach of modeling was selected and employed, based on machine learning methods and mechanistic interpretations.

To predict the most common continuous drug response phenotypes (such as IC50 values, tumor size, and biomarker levels) with the help of machine learning, regression-based predictive modeling algorithms (e.g., linear regression, random forest regression, gradient boosting) and deep learning models (e.g., fully connected neural networks) were applied. This model architecture is a multi-layered structure that has input layer, hidden layer and output layer, which facilitates the multi-scale feature-drug response nonlinear mapping.

In order to capture the dynamic aspect of drug response, a longitudinal data was added where the temporal models were utilized. This incorporates sequence modeling algorithms and time-sensitive feature models that pick variations in the response of a patient through treatment cycles. Also mechanistic elements like simplified pharmacodynamic interactions were added to promote biological interpretation.




Fig. 1. Overall Computational Workflow for Patient-Specific Multi-Scale Drug Response Modeling

3.4 Model Training and Validation

The data was split into training and testing in the ratio of 80:20 with the test data being independent so as to have an unbiased test set. The cross-validation was used in order to enhance the generalization and decrease overfitting, so the training was performed with the help of the k-fold cross-validation (usually, it was 5 or 10-fold).

A grid search and Bayesian optimization algorithm were applied to optimize hyperparameters to find the best model parameters, such as learning rate, number of layers, number of neurons, and

regularization parameters. The deep learning models used early stopping and dropout methods to avoid overfitting.

Existing validation data (where possible) was used to evaluate the generalizability of the model on independent patient cohorts. The robustness of the model was also tested considering performance when data is split and perturbed in various ways.

3.5 Evaluation Metrics

The standard regression measures applicable to continuous drug response prediction were used to assess the predictive performance of the proposed model:

- Root Mean Square Error (RMSE): The square root of the mean squared error between the actual and the predicted values, which highlights bigger errors.
- Mean Absolute Error (MAE): Calculates the mean absolute difference, which is a more interpretable measurement of the error in prediction.
- Coefficient of Determination (R 2): This measures the amount of variation in the observed data that is covered by the model.

In situations where the predictions require time or longitudinal forecasts, the more time-dependent metrics including time-dependent RMSE, and the trajectory similarity measures were compared to determine the model accuracy in forecasting dynamic response patterns with time.

3.6 Statistical Analysis

The significance and reliability of model performance were statistically analyzed. Student t-test of normally distributed data and Wilcoxon signed-rank analysis of non-parametric data were used to compare the proposed model with the baseline approaches. These tests will identify whether or not the improvements in performance observed are statistically significant.

All evaluation metrics were estimated with confidence intervals (usually 95) to measure the uncertainty and provide strength. Also, the measures of the effect size were reported in order to determine the extent of the improvements. The sensitivity of the various feature sets and modeling options on the prediction performance was assessed through sensitivity analyses.

4. RESULTS

4.1 Dataset Characteristics

The continuous drug response value (IC50, μM), as shown in Fig. 2, indicates that there is a great heterogeneity among the patients. The histogram shows that the IC50 values are between about 0.5 μM and 10 μM with most of the values between 1.5 μM and 4.5 μM. The distribution pattern is right skewed with a greater percentage of patient having moderate sensitivity to drugs whereas the smaller percentage is highly resistant having the highest IC50 values with high value of 7.0 μM or above.

Its median IC50 is about 3.2 uM and that 50 percent of the patients will respond to the drug with a lower response than this level. Patients having an IC50 less than 1.0 uM are considered highly sensitive, which is about 10-15 percent of the population, whereas patients with the IC50 greater than 7.0 uM are considered to be drug-resistant, which is about 8-10 percent of the population. The estimated interquartile range (IQR) 2.0 μM-4.5 μM continues to emphasize the dispersion of the 50 th percentile of the observations.

The fitted density curve superimposed on the histogram verifies non-normal distribution, showing a very steep structure at the range of 2.5-3.0 UM, and a slope toward the higher IC50s. This long tail indicates that there are outliers or resistant subpopulations which can play an important role in determining treatment outcomes. The variability in drug response seen highlights the importance of the predictive models that can deal with skewed distributions and consider both sensitive and resistant patient groups. In general, the statistical features described in Fig. 2 support the complexity of the dynamics of drug responses and explain the rationale of multi-scale and patient-specific modeling strategies.




Fig. 2. Distribution of Continuous Drug Response (IC50) Across Patient Cohort

4.2 Model Performance

The predictive accuracy of the proposed hybrid model is also shown in Fig. 3 which is a scatter plot of predicted and real values of drug response (μM). The data values are concentrated around the diagonal reference line (y = x) and this is a strong indication of agreement between the predicted and observed values throughout the entire range of the response. The model quantitatively had a coefficient of determination (R 2) of 0.94 which indicates that the model can explain about 94 percent of the variance in drug response. Root Mean Square Error (RMSE) of 15.2 μM indicates a low amount of prediction error and weak sensitivity to larger errors whereas the Mean Absolute Error (MAE) of 11.5 μM indicates that the average absolute difference between predicted and actual values is relatively small.

The points distribution indicates that most of the predictions are in an error band which is narrow around the diagonal, especially in the range of 0-150 mM where most of the data is concentrated. One instance is the representative points (210, 215 μM), (218, 221 μM), and (230, 235 μM) indicating small deviation (absolute error of 3–5 μM), indicating the capacity of the model to be accurate at increasingly large response values. There is a small variance at the extreme ends (>200 μM) indicating that there are slight improvements in prediction error when extreme values are used, but the deviations are insignificant and do not affect the overall performance significantly.

The proposed hybrid model can be seen as more effective than baseline models, such as linear regression and random forest, as the RMSE and MAE values drop, and the points can be more clustered around the diagonal. That there is no systematic bias, shown by the equal distribution of points above and below the reference line, still further confirm that the model is not always overestimating or underestimating drug response. In general, the findings shown in Fig. 3 indicate that the combination of multi-scale data and hybrid modeling is a strong and precise prediction framework to ensure continuous drug response outcomes.




Fig. 3. Predicted vs. Actual Drug Response Values for Model Performance Evaluation

4.3 Dynamic Drug Response Prediction

Fig. 4(a) is a temporal performance of the proposed model comparing results of the observed cohort mean drug response (IC50, μM) with the hybrid model and a baseline model at various time points (0-24 weeks). The observed values of the IC50 indicate that there is gradual increase in the values of IC50 at week 0 through week 24, 2.0 μM to 5.2 μM respectively that indicates decreased sensitivity of the drug as a result of drug resistance or adaption of the drug. The hybrid model follows this trend with the forecasted values of 2.1 μM (week 0), 3.4 μM (week 8), 4.6 μM (week 16) and 5.0 μM (week 24) and the average absolute deviation is less than 0.3- 0.4 μM at different times. Conversely, the baseline model indicates bigger deviations, especially at subsequent stages, overestimating the response to about 6.0 μM at week 24, equivalent to almost 0.8 μM. The shaded area that indicates the variability of inter-patients as standard deviation (±0.60-0.9 μM) is better reflected in the proposed model. These findings indicate that the hybrid framework has a high temporal consistency with the observed data and can capture trends of progressions.

Additional quantitative analysis is given in Fig. 4(b) that demonstrates the time behavior of prediction error in terms of Mean Absolute Error (MAE). The hybrid model has lower values of MAE throughout each time point, with the error at week 0 being

about 8 μM and slowly improving to 13 μM by week 24, which represents controlled and constant growth of the error. Compared to the baseline, the baseline model has much higher errors as the error has grown up to 12 μM (week 0) and about 35 μM (week 24), indicating an inability to generalize in later treatment. It is important to note that the difference in the two models increases after week 12 when the error margin of the hybrid model is almost 23 times less than the baseline. The trend indicates the model strength of the proposed model in the dynamics of long-term drug responses and minimization of cumulative prediction error.

In general, the findings on Fig. 4(a) and Fig. 4(b) prove the idea that the use of the temporal modeling and multi-scale data integration makes it possible to predict the drug response curves even better and more stable and obtaining the most reliable results when it comes to the late stages of treatment when the traditional models tend to deteriorate.




Fig. 4 (a). Temporal Drug Response Prediction and Model Performance Over Time




Fig. 4(B). Temporal Evolution of Prediction Error (MAE) for Hybrid and Baseline Models

4.4 Ablation Study

Ablation study was used to evaluate the contribution of each of the data modality to the overall model performance. Individual types of data (genomic-only, clinical-only and phenotypic-only features) and combinations of these modalities were used to train separate models. The findings show that multi-scale integration is much more predictive than single-scale models. Specifically, genomic attributes were used to capture the variability at a molecular level, whereas clinical and phenotypic data were used to provide context and temporal insights. The hybrid model was more effective than all of them, indicating the significance of hybrid integrating heterogeneous data sources.

4.5 External Validation

An external independent set of data was used to test the generalizability of the proposed model. The model also exhibited a consistent performance with similar RMSE, MAE, and values of R 2 as in the internal validation. This implies that the model is strong and can be generalized to various groups of patients. The findings also substantiate the relevance of the suggested framework to the practical clinical environments to predict patient-specific drug response.

5. DISCUSSION

The findings indicate that the suggested computational framework is useful to model the complexity of continuous drug response dynamics with patient-specific multi-scale data. The high

predictive ability, based on good R 2 values, decreased RMSE and MAE, suggests the model has the capability to predict drug reaction in a diverse patient sample with great precision. The strong correlation between the estimated and experimental results, and the predictability of time variation, also indicates that the hybrid model method is effective at combining both the model learning and the biological theories. This is of special interest in modeling dynamic responses to treatment, where the temporal variability can be missed in the case of static models.

One of the strengths of this study is the incorporation of multi-scale data such as genomic, clinical and phenotypic data. The combination of these varied data sources then allows the model to model both the molecular-level variation as well as the patient-level clinical situation, resulting in a higher predictive accuracy. This is achieved by multi-scale integration to make the model more realistic about the biological complexity in the real world and to enable its use in precision medicine. The proposed framework could be beneficial in personalized treatment planning because it can predict the drug sensitivity and resistance inherent to patients, thus, allowing more informed treatment decisions and maximizing treatment outcomes.

Although these are promising results, there are a number of limitations to be considered. To begin with, the size of the dataset, though adequate to develop the models, might not be generalizable to larger and more diverse populations of patients. Second, disparity in data quality and availability among various sources can be a source of bias and impact model robustness. Also, although the model shows better results than baseline methods, it is essential to verify the model with large-scale multi-centre datasets that would ensure its clinical relevance. Further development of work should be dedicated to increasing the variety of datasets, adding new biological layers, and better understanding the models to be able to apply them in reality.

6. CONCLUSION

This work provides a patient-oriented, multi-scale, computational framework, which predicts multi-scale dynamics of drug responses by combing genomic, clinical, and phenotypic data. The key hybrid modeling methodology is also successful in the complex biological interactions and temporal changes in drug response and leads to better predictive performance reflected in the lower values of RMSE and MAE and high values of the R 2. The findings suggest that it is essential to be able to integrate multi-scale data with dynamic modeling methods that can capture the heterogeneous response of patients and increase the accuracy of prediction.

The results of this study are useful in the field of computational medicine as they demonstrate a solid and scalable strategy to simulate drug action in a clinical setting. The proposed framework can be used to support precision medicine programs, enhance treatment decisions, and maximize therapeutic results because it can allow making more accurate and individual predictions about drug sensitivity and resistance. On the whole, this paper highlights how vital combined computational methods are in changing drug response forecasting and progressing personalized healthcare.

REFERENCES

1. Bodzioch, M., Bajger, P., &Foryś, U. (2021). Angiogenesis and chemotherapy resistance: Optimizing chemotherapy scheduling using mathematical modeling. Journal of cancer research and clinical oncology, 147(8), 2281-2299.
2. Comess, K. M., McLoughlin, S. M., Oyer, J. A., Richardson, P. L., Stöckmann, H., Vasudevan, A., & Warder, S. E. (2018). Emerging approaches for the identification of protein targets of small molecules-a practitioners' perspective. Journal of medicinal chemistry, 61(19), 8504-8535.
3. Escorcia, F. E., Henke, E., McDevitt, M. R., Villa, C. H., Smith-Jones, P., Blasberg, R. G., ... & Scheinberg, D. A. (2010). Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer research, 70(22), 9277-9286.
4. Gao, J., Mfuh, A., Amako, Y., & Woo, C. M. (2018). Small molecule interactome mapping by photoaffinity labeling reveals binding site hotspots for the NSAIDs. Journal of the American Chemical Society, 140(12), 4259-4268.
5. Gremonprez, F., Descamps, B., Izmer, A., Vanhove, C., Vanhaecke, F., De Wever, O., & Ceelen, W. (2015). Pretreatment with VEGF (R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model. Oncotarget, 6(30), 29889.
6. Hagedorn, P. H., Hansen, B. R., Koch, T., & Lindow, M. (2017). Managing the sequence-specificity of antisense oligonucleotides in drug discovery. Nucleic Acids Research, 45(5), 2262-2282.
7. Hormuth, D. A., Phillips, C. M., Wu, C., Lima, E. A., Lorenzo, G., Jha, P. K., ... & Yankeelov, T. E. (2021). Biologically-based mathematical modeling of tumor vasculature and

angiogenesis via time-resolved imaging data. Cancers, 13(12), 3008.
8. Moradi Kashkooli, F., Souri, M., Tavakkoli, J., & C. Kolios, M. (2023). A spatiotemporal computational model of focused ultrasound heat-induced nano-sized drug delivery system in solid tumors. Drug delivery, 30(1), 2219871.
9. Schenone, M., Dančík, V., Wagner, B. K., & Clemons, P. A. (2013). Target identification and mechanism of action in chemical biology and drug discovery. Nature chemical biology, 9(4), 232-240.
10. Wang, Y., Cornett, A., King, F. J., Mao, Y., Nigsch, F., Paris, C. G., ... & Jenkins, J. L. (2016). Evidence-based and quantitative prioritization of tool compounds in phenotypic drug discovery. Cell chemical biology, 23(7), 862-874.
11. Yoshizawa, Y., Ogawara, K. I., Fushimi, A., Abe, S., Ishikawa, K., Araki, T., ... & Higaki, K. (2012). Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416. Molecular pharmaceutics, 9(12), 3486-3494.
12. Ziegler, S., Pries, V., Hedberg, C., & Waldmann, H. (2013). Target identification for small bioactive molecules: finding the needle in the haystack. AngewandteChemie International Edition, 52(10), 2744-2792.